MacroGenics(NASDAQ) MGNX

Market Cap$234.55M

Since IPO (2013)-85%

5 Year-85%

1 Year+137%

1 Month-20%

$3.69

-2.38%

-0.09Today

After hours$3.70+$0.01 (+0.14%)

MacroGenics last closing stock price
Metric	Price	Date
Last close	USD 3.69	2026-07-31

MacroGenics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-0.27%	USD 3.70	2026-07-24
1 month	-20.13%	USD 4.62	2026-07-01
3 month	+17.89%	USD 3.13	2026-05-01
Year to date	+129.19%	USD 1.61	2025-12-31
1 year	+136.54%	USD 1.56	2025-07-31
3 year	-24.39%	USD 4.88	2023-08-01
5 year	-85.22%	USD 24.96	2021-07-30
Since inception	-85.23%	USD 24.99	2013-10-10

MacroGenics Financials at a Glance

Market Cap

$234.55M

Revenue (TTM)

$157.08M

Net Income (TTM)

-$70.36M

EPS (TTM)

-$1.11

P/E Ratio

-3.32

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Price

$3.69

Volume

410,834.21

Open

$3.79

Price

$3.69

Volume

410,834.21

Open

$3.79

Previous Close

$3.69

Daily Range

$3.61 - $3.80

52-Week Range

$1.29 - $5.08

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

1.44 (Average)

Price

$3.69

Volume

410,834.21

Open

$3.79

Previous Close

$3.69

Daily Range

$3.61 - $3.80

52-Week Range

$1.29 - $5.08

Estimated Earnings Date

Aug 13, 2026

MGNX News

Page 1

MGNX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MacroGenics

MacroGenics makes medicines to treat different types of cancer. The company uses proteins to find and attack cancer cells. These treatments help patients who have few other medical options.

Medicines in the Pipeline

Contract Manufacturing: Manufacturing services provided to external partners for clinical and commercial products; accounts for 68% of revenue.
Royalty Revenue: Payments received from partners based on sales of approved drugs like ZYNYZ; accounts for 30% of revenue.
Antibody-Drug Conjugates: Targeted therapies that deliver potent drugs directly to cancer cells while sparing healthy tissue.
Bispecific Molecules: Engineering technology that allows a single medicine to bind to two different targets at once.

Strategic Moves and Partnerships

Sold the rights to future ZYNYZ royalties to Sagard for an initial $70 million payment in June 2025.
Agreed to sell manufacturing operations to Bora Pharmaceuticals for $122.5 million in May 2026.
Formed a partnership with Gilead in 2022 to develop bispecific antibodies for cancer treatment.
Received an additional $60 million from Sagard in May 2026 to expand a royalty purchase agreement.
Established a three-year manufacturing deal with Incyte in September 2025 to produce bulk drug substances.

Engineering Better Antibodies

MacroGenics uses its proprietary DART and TRIDENT platforms to design antibodies that can engage multiple biological targets. These specialized technologies help the company create medicines for patients with complex solid tumors and blood cancers.

Recent Financial Performance

Total revenue reached $20.8 million in Q1 2026, up 57.5% from the same period in 2025.
Net loss was $36.8 million in Q1 2026, which narrowed by 10.4% compared to the previous year.
Operating cash flow was negative $35.8 million in Q1 2026, an improvement of 23.6% year-over-year.
Research and development expenses fell to $35 million in Q1 2026, a 12% decrease from 2025.
Cash and marketable securities totaled $154.2 million at the end of March 2026.

Bottom Line

MacroGenics has transitioned from a research firm to a developer with approved products and several high-level partnerships. By selling non-core manufacturing assets and royalty rights, the company is focusing its resources on its drug pipeline.

AI Generated • May 14, 2026

Industry

Biotechnology

Sector

Health Care

Employees

293

CEO

Eric Risser, MBA

Website

www.macrogenics.com

Headquarters

Rockville, MD 20850, US

MGNX Financials

Key Financial Metrics (TTM)

Gross Margin

69.93%

Operating Margin

-40.53%

Net Income Margin

-44.79%

Return on Equity

-147.80%

Return on Capital

-44.87%

Return on Assets

-32.29%

Earnings Yield

-30.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$234.55M

Shares Outstanding

63.56M

Volume

410.83K

Avg. Volume

1.18M

Financials (TTM)

Gross Profit

$109.85M

Operating Income

-$63.66M

EBITDA

-$50.64M

Operating Cash Flow

-$69.96M

Capital Expenditure

-$1.73M

Free Cash Flow

-$71.69M

Cash & ST Invst.

$154.23M

Total Debt

$36.51M

MacroGenics Performance Analysis

MacroGenics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 151,941,000	96.2%
2023	2023-12-31	USD 58,749,000	-61.3%
2024	2024-12-31	USD 149,962,000	155.3%
2025	2025-12-31	USD 149,500,000	-0.3%

MacroGenics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	68.6%
Q3	2025-09-30	227.5%
Q4	2025-12-31	-43.4%
Q1	2026-03-31	-49.6%

MacroGenics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.95	-42.2%
2023	2023-12-31	USD -0.15	-92.5%
2024	2024-12-31	USD -1.07	631.0%
2025	2025-12-31	USD -1.18	10.5%

MacroGenics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	12.3%
Q3	2025-09-30	147.4%
Q4	2025-12-31	-181.5%
Q1	2026-03-31	-163.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$20.78M

+57.5%

Gross Profit

$9.56M

+58.7%

Gross Margin

46.01%

N/A

Market Cap

$234.55M

N/A

Market Cap/Employee

$800.50K

N/A

Employees

293

N/A

Net Income

-$36.77M

+10.4%

EBITDA

-$30.20M

+22.9%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$154.23M

+0.1%

Total Debt

$36.51M

-2.6%

Accounts Receivable

$10.43M

-1.1%

Inventory

$9.50M

+0.8%

Long Term Debt

$31.30M

-2.5%

Short Term Debt

$5.21M

-2.9%

Return on Assets

-32.29%

N/A

Return on Invested Capital

-52.21%

N/A

Free Cash Flow

-$36.16M

+23.8%

Operating Cash Flow

-$35.81M

+23.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

WHWKWhitehawk Therapeutics Inc

WHWKWhitehawk Therapeutics Inc$3.85+0.00%

ORMPOramed Pharmaceuticals Inc.

ORMPOramed Pharmaceuticals Inc.$4.07-1.21%

ZNTLZentalis Pharmaceuticals, Inc.

ZNTLZentalis Pharmaceuticals, Inc.$4.74-3.66%

STTKShattuck Labs, Inc.

STTKShattuck Labs, Inc.$7.07-1.67%

CNTBConnect Biopharma Holdings Limited

CNTBConnect Biopharma Holdings Limited$2.02-3.35%

IFRXInflaRx N.V.

IFRXInflaRx N.V.$1.70-1.16%

COYACoya Therapeutics, Inc.

COYACoya Therapeutics, Inc.$4.19+2.70%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$200.75+0.03%

AAPLApple

AAPLApple$308.91-0.07%

AMZNAmazon

AMZNAmazon$271.58+0.15%

INTCIntel

INTCIntel$90.20-0.01%

FCUVFocus Universal

FCUVFocus Universal$11.60+5.17%

NOKNokia

NOKNokia$9.14+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.62+0.02%

Questions About MGNX

What is the current price of MacroGenics?

MacroGenics is trading at $3.69 per share.

What is the 52-week range for MacroGenics?

Over the past 52 weeks, MacroGenics has traded between $1.29 and $5.08.

How much debt does MacroGenics have?

As of the most recent reporting period, MacroGenics reported total debt of $105.22M.

How much cash does MacroGenics have on hand?

MacroGenics reported $66.52M in cash and cash equivalents in its most recent financial results.

What is MacroGenics’s dividend yield?

MacroGenics does not currently have a dividend yield.

MacroGenics(NASDAQ) MGNX

MacroGenics Financials at a Glance

MGNX News

MacroGenics Revenue Doubles in Q2

Why Shares of MacroGenics Are Jumping Thursday

Why MacroGenics Stock Inched Higher on Monday

Why MacroGenics Stock Tumbled Today

Why Shares of MacroGenics Climbed Thursday

Why Shares of MacroGenics Jumped Thursday

Why Shares of MacroGenics Were Dropping Tuesday

Why MacroGenics Stock Crushed the Market on Monday

MGNX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About MacroGenics

Medicines in the Pipeline

Strategic Moves and Partnerships

Engineering Better Antibodies

Recent Financial Performance

Bottom Line

MGNX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

MacroGenics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MGNX

What is the current price of MacroGenics?

What is the 52-week range for MacroGenics?

How much debt does MacroGenics have?

How much cash does MacroGenics have on hand?

What is MacroGenics’s dividend yield?

Premium Investing Services